Quick Answer
ARROWHEAD PHARMACEUTICALS, INC. reported Operating Income Loss of $98.35 million for the year ending 2025.
- ARROWHEAD PHARMACEUTICALS, INC. showed an increase of +116.4% in Operating Income Loss from 2024 to 2025.
- This data is from ARROWHEAD PHARMACEUTICALS, INC.'s annual report (Form 10-K), filed with the SEC on November 25, 2025.
- XBRL data for this metric is available from 2011 to 2025 (15 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 15 years of available data (2011 to 2025), ARROWHEAD PHARMACEUTICALS, INC.'s Operating Income Loss has grown by 1,100.4%.
- Historical annual values: Fiscal year 2025: $98.35 million | Fiscal year 2024: -$601.08 million | Fiscal year 2023: -$205.00 million | Fiscal year 2022: -$178.51 million | Fiscal year 2021: -$149.04 million | Fiscal year 2020: -$93.16 million | Fiscal year 2019: $61.19 million | Fiscal year 2018: -$55.94 million | Fiscal year 2017: -$37.00 million | Fiscal year 2016: -$81.74 million | Fiscal year 2015: -$95.97 million | Fiscal year 2014: -$53.28 million | Fiscal year 2013: -$24.59 million | Fiscal year 2012: -$21.09 million | Fiscal year 2011: -$9.83 million.
- Data sourced from SEC EDGAR public filings as of June 20, 2026.
Last verified: